Full-Time

Principal Scientist

Protein Analytics & Biophysics-Target Binding

Posted on 7/29/2024

Generate Biomedicines

Generate Biomedicines

201-500 employees

Generates novel medicines using generative biology

No salary listed

Senior, Expert

Cambridge, MA, USA

Category
Lab & Research
Interdisciplinary Research
Life Sciences
Required Skills
Data Analysis
Requirements
  • PhD in a scientific field of study and 8+ years of relevant research experience, Master’s degree in a scientific field of study and 14 years of relevant research experience, or B.S. in a science-related discipline with 16+ years of relevant research experience. Industry experience is required
  • Deep expertise and extensive hands-on experience in biomolecular interaction analysis using biosensor-based platforms (Carterra LSA, Biacore, Octet) and solution-based approaches (KinExA, Gyrolab) is required
  • Highly skilled in experimental design with a strong ability to analyze, interpret and communicate complex kinetic and mechanistic data
Responsibilities
  • Drive the design and execution of fit-for-purpose binding assays and workflows using techniques such as surface plasmon resonance (SPR), bio-layer interferometry (BLI) and kinetic exclusion assay (KinExA) in alignment with program goals and with broader organizational objectives
  • Demonstrate a proven track record of efficiently collating, analyzing, visualizing, interpreting and communicating complex data sets using a repertoire of digital tools
  • Pioneer efforts to maximize productivity, streamline processes and expand machine learning capabilities by integrating new and innovative technologies
  • Collaborate with computational scientists and multidisciplinary project teams to support critical decision-making checkpoints throughout discovery process
  • Provide technical oversight and strategic guidance to functional team members
Generate Biomedicines

Generate Biomedicines

View

Generate Biomedicines focuses on creating new medicines by combining machine learning, biological engineering, and medicine. The company uses a method called generative biology, which involves analyzing millions of proteins to learn how nature encodes their functions. This knowledge allows them to design new medicines tailored for specific therapeutic needs. Their main product, The Generate Platform, enables the rapid production of medicines across various therapeutic areas, significantly improving the drug discovery process compared to traditional methods. Unlike many competitors, Generate Biomedicines emphasizes a proactive approach to medicine creation, aiming to democratize access to biotherapeutics. The company's goal is to expand its capabilities in generating and testing proteins, having already produced 42,000 proteins, and to continue advancing the field of therapeutics.

Company Size

201-500

Company Stage

Series C

Total Funding

$693M

Headquarters

Somerville, Massachusetts

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • Generative AI is enhancing Generate Biomedicines' drug discovery capabilities.
  • Strategic alliances, like with Novartis, leverage AI for drug development.
  • Samsung's investment indicates strong market confidence in Generate Biomedicines.

What critics are saying

  • Intellectual property disputes may arise as the generative biology platform expands.
  • Technological advancements may render current platforms obsolete without continuous innovation.
  • Reliance on partnerships could pose risks if collaborations don't meet expectations.

What makes Generate Biomedicines unique

  • Generate Biomedicines uses generative biology to create protein-based medicines efficiently.
  • The Generate Platform allows rapid production of medicines across multiple therapeutic areas.
  • The company integrates machine learning with biological engineering for innovative drug discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
BioSpace
Jan 9th, 2025
Generate:Biomedicines Provides Update on its Platform and Pipeline Powered by AI at the 43rd Annual J.P. Morgan Healthcare Conference

Generate:Biomedicines provides update on its platform and pipeline powered by AI at the 43rd Annual J.P. Morgan Healthcare Conference.

PR Newswire
Jan 9th, 2025
Generate:Biomedicines Provides Update On Its Platform And Pipeline Powered By Ai At The 43Rd Annual J.P. Morgan Healthcare Conference

SOMERVILLE, Mass., Jan. 9, 2025 /PRNewswire/ -- Generate:Biomedicines ("Generate") today announced that Mike Nally, Chief Executive Officer, will provide an update on the company's platform, which combines generative AI and experimental innovation, and its advancing pipeline at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13 at 7:30am PST. The Generate Platform has proven its ability to produce unique and differentiated molecules, allowing the company to advance multiple programs into clinical development and establishing programmable biology as a catalyst for new possibilities in medicine. "We are at the forefront of a biological revolution," said Mike Nally, CEO of Generate:Biomedicines. "Generative AI is enabling us to tackle some of the toughest challenges in drug discovery, from historically undruggable and hard-to-drug targets to optimizing molecules with unprecedented precision

PR Newswire
Dec 18th, 2024
Samsung Invests In Generate: Biomedicines To Advance Ai-Driven Protein Therapeutics Discovery

- Samsung Life Science Fund invests in Generate:Biomedicines, a Flagship Pioneering company leading in AI-enabled protein therapeutics discovery and development- Investment highlights Samsung's dedication to advancing innovation and creating a robust ecosystem for AI-enabled therapeutic developmentINCHEON, South Korea, Dec. 18, 2024 /PRNewswire/ -- Samsung announced today it has invested in Generate: Biomedicines ("Generate") as part of its efforts to drive growth and innovation in the biopharmaceutical sector. The investment was made via the Samsung Life Science Fund, which was created jointly between Samsung Biologics, Samsung C&T, and Samsung Bioepis, and managed by Samsung Venture Investment Corporation. Established in 2021 and worth KRW 240 billion, the fund has invested in biotech companies with promising technologies.Generate, founded by Flagship Pioneering, is a US-based clinical stage company leading in generative biology. The company applies AI-based optimization and de novo generation to discover and design novel protein therapeutics, and has a robust pipeline of approximately 20 programs from preclinical to clinical development across oncology, immunology, and infectious diseases."We see great potential in Generate to develop first- and best-in-class therapeutics," said John Rim, President and CEO of Samsung Biologics. "Leveraging Generate's strengths in AI and machine learning, we look forward to creating an ecosystem for development, manufacturing, and R&D collaboration to advance next-generation medicines in areas with unmet needs.""Funding from leading partners like Samsung enables us to continue advancing our platform, generating high-quality data, and empowering our exceptional team to tackle some of the toughest challenges in human health," said Mike Nally, CEO of Generate:Biomedicines

Labiotech
Oct 10th, 2024
12 Biotech Unicorns Revolutionizing The Future Of Healthcare

Have you ever heard of a biotech unicorn? Although a mythological creature might be what first springs to mind, a unicorn in the business world actually refers to a privately owned company valued at more than $1 billion. Some world-renowned former unicorns include Airbnb, Facebook, and Google. The reason they are called “unicorns” is because it is traditionally very rare for a company to achieve this valuation.In the biotech world, there are only a select few companies with unicorn status that are working on therapeutics. In this article, we take a closer look at 12 biotech unicorns rated in order of their valuations according to CB Insights.Table of contentsAbogen BiosciencesAbogen Biosciences is a Chinese biotech company and is valued at $3.7 billion. This comes as no surprise after it raised $700 million in series C funding back in August 2021, marking one of the largest private biotech funding rounds ever and obliterating the fundraising record for a Chinese mRNA vaccine developer. It then followed this round with another impressive series C+ round in November of the same year, in which it raised $300 million.Abogen is part of a rare breed of Chinese biotechs, having actually developed all of its key messenger RNA (mRNA) platform technologies itself, across mRNA synthesis, delivery, and manufacturing

Pharma Industry Review
Sep 25th, 2024
Generate and Novartis Forge $1B+ Alliance for AI-Powered Protein Therapeutics

Beyond these high-profile partnerships, Generate also recently completed a $273 million Series C funding round, backed by key investors including Amgen and NVIDIA.

INACTIVE